Trial · NCT02057757
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Hospital Discharge | Measured through Day 28 | The time to hospital discharge measured through Day 28. |
| Secondary | Number of Participants Hospitalized on Days 3, 7, 14, and 28 | Measured at Day 3, Day 7, Day 14, and Day 28 | The number of study participants (e.g., adults and children) who were hospitalized on Days 3, 7, 14, and 28. |
| Secondary | Number of Participants Who Died Within the First 5 Days | Measured within First 5 Days | Total Deaths of Participants, including Deaths within First 5 Days |
| Secondary | Number of Participants Who Experienced Clinical Symptoms | Measured through Day 28 | Measured daily through Study Day 14 and then again on Study Day 28 |
| Secondary | Duration of Fever in Study Participants | Measured each day through Day 14 and on Day 28 | Study participants' duration (hours) of fever measured daily through Day 14 and then again on Day 28. The total duration in hours from the visit when fever was registered for the study participant until the next visit when no fever was registered for the study participant. |
| Secondary | Number of Participants Who Require Oxygen Use | Measured through Day 28 or participants' last day of hospitalization | Number of study participants who require use of supplemental oxygen at time points (e.g., Any time, Day 0, Day 3, Day 7, Day 14, and Day 28) |
| Secondary | Number of Study Participants (e.g., Adult and Children) Admitted to the Intensive Care Unit (ICU) by Time Point (Anytime, Day 0, Day 3, Day 7, Day 14, Day 28) | Measured through Day 28 or participants' last day in the ICU | Number of study participants (e.g., adult and children) admitted to the intensive care unit (ICU) by time point (Anytime, Day 0, Day 3, Day 7, Day 14, Day 28); worst case imputed. |
| Secondary | Study Participants (e.g., Adults, Children) Requiring Mechanical Ventilation at Study Time Points (Any Time, Day 0, Day 3, Day 7, Day 14, Day 28) | Measured through Day 28 or participants' last day of hospitalization | Study participants (e.g., adults, children) requiring mechanical ventilation (e.g., intubation/extubation) at study time points (Any Time, Day 0, Day 3, Day 7, Day 14, Day 28); worst case imputed. |
| Secondary | Number of Study Participants With the Presence of Complications (Pneumonia, Respiratory Failure Requiring Mechanical Ventilation, Acute Respiratory Distress Syndrome [ARDS], Sepsis, or Bronchiolitis) During Study | Measured through Day 28 or participants' last day of hospitalization | Number of study participants (e.g., adults and children) with the presence of a complication (pneumonia, respiratory failure requiring mechanical ventilation, acute respiratory distress syndrome \[ARDS\], sepsis, or bronchiolitis) during the study . |
| Secondary | Duration (Days) Until Affirmative Global Assessment (e.g., Answered Yes) by Study Participants (e.g., Adults, Children) | Measured daily through Day 14 and on Day 28 | Study participant (e.g., adults and children) answers (e.g., yes) to global assessment questions measured daily through Day 14 and then again on Day 28. |
| Secondary | Number of Participants Using Antibiotics/Antivirals During Hospitalization | Measured through participants' first 5 days of hospitalization | Number of study participants taking an Antibiotic or Anti-Influenza Antiviral during first 5 days of hospitalization. |
| Secondary | Number of Participants Who Are Re-hospitalized Within 28 Days | Measured through Day 28 | Number of study participants (e.g., adults and children) who were re-hospitalized within 28 days (e.g., days from randomization). |
| Secondary | Use of Systemic Corticosteroids | Measured within First 5 Days | Number of study participants taking Systemic Steroids during first 5 days. |
| Secondary | Presence of Virus on Nasopharyngeal (NP) Swab at Day 3 (Same Virus as Day 0) | Measured through Day 3 | Study participants with Detectable Virus on nasopharyngeal (NP) swab at Baseline and at Day 3. |
| Secondary | Number of Participants Reporting Adverse Events (AEs) | Measured through Day 28 or participants' last day of hospitalization | Number of study participants with at least one Adverse Event During Study Duration |
| Secondary | Number of Participants Reporting Serious Adverse Events (SAEs) | Measured through Day 28 or participants' last day of hospitalization | Number of study participants (e.g., adults and children) reporting at least one serious adverse events (SAEs). |
| Secondary | Chemistry Laboratory Assessments (Creatinine, Total Bilirubin) on Days 3, 7, and 28 | Measured on Day 3, Day, 7 and Day 28 | Laboratory values for chemistry laboratory assessments (e.g., Creatinine and Total Bilirubin) on Days 3, 7, and 28. |
| Secondary | Chemistry Laboratory Assessments (ALT, AST, LDH) on Days 3, 7, and 28 | Measured on Day 3, Day 7, and Day 28 | Chemistry laboratory assessments (e.g., ALT, AST, and LDH) on Days 3, 7, and 28. |
| Secondary | Chemistry Laboratory Assessment (CRP) on Days 3, 7, and 28 | Measured on Day 3, Day, 7 and Day 28 | Lab Values for chemistry laboratory assessment (e.g., CRP) on Days 3, 7, and 28. |
| Secondary | Hematologic Laboratory Assessments (Neutrophils, Lymphocytes, Eosinophils, and Hematocrit) on Days 3, 7, and 28 | Measured on Day 3, Day, 7 and Day 28 | Hematology laboratory assessments (e.g., Neutrophils, Lymphocytes, Eosinophils, and Hematocrit) on Days 3, 7, and 28. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02057757/registered